SCHEMBL17426416

SCHEMBL17426416

c1ccc(-c2ccc(N(c3ccc(-c4ccccc4)cc3)c3ccc(-n4c5ccccc5c5c6oc7c(ccc8c7c7ccccc7n8-c7ccc(N(c8ccc(-c9ccccc9)cc8)c8ccc(-c9ccccc9)cc8)cc7)c6ccc54)cc3)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ATM Q13315 1/20 0.39
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 1/20 0.36
BRCA1 P38398 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HDAC4 P56524 1/20 0.34
IL1R1 P14778 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
EDNRB P24530 1/20 0.31
EDNRA P25101 1/20 0.31
TSPO P30536 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17426265 0.99 L3MBTL1 (0.38) L3MBTL1KDM4EATMKMT2AMEN1
SCHEMBL17426393 0.99 L3MBTL1 (0.38) L3MBTL1KDM4EATMKMT2AMEN1
SCHEMBL17426264 0.99 L3MBTL1 (0.38) L3MBTL1KDM4EATMKMT2AMEN1
SCHEMBL17426278 0.99 L3MBTL1 (0.38) L3MBTL1KDM4EATMKMT2AMEN1
SCHEMBL17426396 0.99 L3MBTL1 (0.38) L3MBTL1KDM4EATMKMT2AMEN1
SCHEMBL17426258 0.97 L3MBTL1 (0.41) L3MBTL1KDM4EATMKMT2AMEN1
SCHEMBL19695718 0.97 L3MBTL1 (0.41) L3MBTL1KDM4EATMKMT2AMEN1
SCHEMBL17426261 0.96 L3MBTL1 (0.41) L3MBTL1KDM4EATMKMT2AMEN1
SCHEMBL19695726 0.95 MEN1 (0.36) L3MBTL1KDM4EATMKMT2AMEN1
SCHEMBL17426408 0.94 MEN1 (0.35) L3MBTL1KDM4EATMKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9842996-B2 Amine compound having hetero-fused ring and organic electroluminescent element using amine compound IDEMITSU KOSAN CO., LTD. (JP) 2017-12-12 US disclosed
US-9842996-B2 Amine compound having hetero-fused ring and organic electroluminescent element using amine compound IDEMITSU KOSAN CO., LTD. (JP) 2017-12-12 US disclosed
US-20160013419-A1 AMINE COMPOUND HAVING HETERO-FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT USING AMINE COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2016-01-14 US disclosed
US-20160013419-A1 AMINE COMPOUND HAVING HETERO-FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT USING AMINE COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2016-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160013419-A1 AMINE COMPOUND HAVING HETERO-FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT USING AMINE COMPOUND CTCF, SAT1, TEAD2 L3MBTL1 2674/4885KDM4E 942/4885ATM 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.